Collectively, these results demonstrate that ATAD2 inhibition via BAY-850 leads to cell-cycle arrest and apoptosis induction, which, in turn, suppresses ovarian cancer growth and progression. This evidence concerns the gene ATAD2 and ovarian cancer.